A US FDA advisory committee's endorsement of US WorldMeds LLC's Lucemyra (lofexidine) for mitigating the symptoms of abrupt opioid withdrawal came with advice for future sponsors on the evidentiary threshold for demonstrating a clinically meaningful benefit for withdrawal treatments.
While many members of the Psychopharmacologic Drugs Advisory Committee believe data on opioid withdrawal symptom mitigation are enough to support...





